BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/10/2014 7:09:00 PM | Browse: 238 | Download: 529
Publication Name World Journal of Gastroenterology
Manuscript ID 10205
Country of Manuscript Source Taiwan
Received
2014-03-19 09:33
Peer-Review Started
2014-03-19 11:34
To Make the First Decision
2014-04-15 19:39
Return for Revision
2014-04-23 21:05
Revised
2014-05-07 22:58
Second Decision
2014-06-13 11:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-13 12:32
Articles in Press
2014-06-13 13:02
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-10-27 15:55
Publish the Manuscript Online
2014-11-10 19:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript Type Minireviews
Article Title Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy
Manuscript Source Invited Manuscript
All Author List Man-Hsin Hung, Wei-Tien Tai, Chung-Wai Shiau and Kuen-Feng Chen
Funding Agency and Grant Number
Correspondence To Kuen-Feng Chen, MD, PhD, Department of Medical Research, National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. kfchen1970@ntu.edu.tw
Keywords Hepatocellular carcinoma; Sorafenib; Signal transducer and activator of transcription 3; Target therapy; Kinase-independent
Core Tip Hepatocellular carcinoma (HCC) is one of the major cancers worldwide, for which the only approved target therapy is sorafenib. In addition to its previously characterized kinase inhibition, sorafenib also acts via a kinase-independent mechanism to target signal transducer and activator of transcription 3 (STAT3) signaling in HCC cells. This review discusses these findings, adding to the knowledge concerning the mechanisms of action of sorafenib as well as exploring the potential use of STAT3 as a therapeutic target in future cancer drug development.
Publish Date 2014-11-10 19:10
Citation Hung MH, Tai WT, Shiau CW, Chen KF. Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol 2014; 20(41): 15269-15274
Url http://www.wjgnet.com/1007-9327/full/v20/i41/15269.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i41.15269
Full Article (PDF) WJG-20-15269.pdf
Full Article (Word) WJG-20-15269.doc
Revised Manuscript 10205-Review.docx
Peer-review Report 10205-Peer review.pdf
Answering Reviewers 10205-Answering reviewers.pdf
Scientific Misconduct Check 10205-CorssCheck.jpg
Scientific Editor Work List 10205-Scientific editor work list.pdf
Copyright License Agreement 10205-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 10205-Language certificate.pdf